SEC Form 4 · accession 0001725092-26-000006

Cue Biopharma, Inc. · CUE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Jul 9, 2026

Accepted (ET)

Jul 10, 2026 · 7:32 pm EDT

Rule 10b5-1 plan

box not checked

Issuer CIK

0001645460

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jul 9, 2026	A	327,537	$0.00	A	655,074	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Common Stock^F2	—	Jul 9, 2026	A	327,537	A	—	—	Common Stock	327,537	327,537	D

F1Represents that grant of restricted stock units ("RSUs"). The shares subject to the RSUs vest in equal quarterly installments over a period of forty-eight (48) months, measured from the date of grant, subject to the reporting person's continued service with the issuer through each vest date.
F2Represents the grant of performance stock units ("PSUs"). The PSUs are subject to certain stock-price based vesting conditions with vesting comprised of three substantially equal tranches that are eligible to vest based the achievement of a closing price per share of $33.00, $38.50 and $44.00, in each case for a period of five consecutive trading days. If the stock price targets are not satisfied by the period ending 24 months from the date of grant, the PSUs shall automatically be forfeited and cancelled without consideration.